MNG635
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.309
- INTERFERON_ALPHA_RESPONSE+0.306
- INFLAMMATORY_RESPONSE+0.274
- IL2_STAT5_SIGNALING+0.259
- ALLOGRAFT_REJECTION+0.252
- KRAS_SIGNALING_UP+0.251
- COMPLEMENT+0.220
- TGF_BETA_SIGNALING+0.215
- COAGULATION+0.212
- BILE_ACID_METABOLISM+0.201
Top 10 suppressed
- G2M_CHECKPOINT-0.488
- E2F_TARGETS-0.482
- MYC_TARGETS_V2-0.428
- MITOTIC_SPINDLE-0.396
- DNA_REPAIR-0.291
- OXIDATIVE_PHOSPHORYLATION-0.289
- MYC_TARGETS_V1-0.262
- MTORC1_SIGNALING-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.190
- GLYCOLYSIS-0.141
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R232 | — | — | 0.890 |
| 2 | TCGA-91-7771-01A-11R-2170-07 | — | cohortA2 | 0.885 |
| 3 | TCGA-49-4505-01A-01R-1206-07 | — | cohortA1 | 0.877 |
| 4 | TCGA-22-4596-01A-01R-1201-07 | — | cohortA1 | 0.873 |
| 5 | TCGA-UF-A7JJ-01A-11R-A34R-07 | — | — | 0.872 |
| 6 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.871 |
| 7 | TCGA-64-1681-01A-11R-2066-07 | — | cohortA1 | 0.871 |
| 8 | TCGA-55-8091-01A-11R-2241-07 | — | cohortA1 | 0.868 |
| 9 | SRR8518195 | — | A | 0.863 |
| 10 | BS_02NZT8CE | low-grade glioma | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.309 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.306 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.274 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.259 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.252 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.251 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.215 | Inavolisib | — uncovered |
| COAGULATION | 0.212 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.201 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.196 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.177 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.175 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.169 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.164 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.155 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.145 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.107 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.099 | Remibrutinib | — uncovered |
| HYPOXIA | 0.096 | Idelalisib | — uncovered |